147 related articles for article (PubMed ID: 29136019)
1. Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
Jeon HG; Yoo JH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM; Ferrari M; Brooks JD; Chung BI
PLoS One; 2017; 12(11):e0186026. PubMed ID: 29136019
[TBL] [Abstract][Full Text] [Related]
2. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.
Jalloh M; Myers F; Cowan JE; Carroll PR; Cooperberg MR
Eur Urol; 2015 Mar; 67(3):451-7. PubMed ID: 24746973
[TBL] [Abstract][Full Text] [Related]
3. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
4. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.
Schiffmann J; Wenzel P; Salomon G; Budäus L; Schlomm T; Minner S; Wittmer C; Kraft S; Krech T; Steurer S; Sauter G; Beyer B; Boehm K; Tilki D; Michl U; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2015 Jul; 33(7):329.e13-9. PubMed ID: 25960411
[TBL] [Abstract][Full Text] [Related]
6. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
7. Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance.
Park HJ; Ha YS; Park SY; Kim YT; Lee TY; Kim JH; Lee DH; Kim WJ; Kim IY
Urol Int; 2013; 90(3):301-5. PubMed ID: 23391718
[TBL] [Abstract][Full Text] [Related]
8. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
[TBL] [Abstract][Full Text] [Related]
9. Role of Chronic Inflammation as a Predictor of Upstaging/Upgrading in Prostate Cancer: Finding a New Group Eligible for Active Surveillance.
Nowroozi MR; Ayati M; Amini E; Aghamiri SM; Momeni SA; Ohadian Moghadam S; Valizadeh F
Urol J; 2020 Jun; 17(4):370-373. PubMed ID: 31953833
[TBL] [Abstract][Full Text] [Related]
10. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Urol Oncol; 2022 Sep; 40(9):407.e9-407.e19. PubMed ID: 35817649
[TBL] [Abstract][Full Text] [Related]
12. Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols.
Kim TH; Jeon HG; Choo SH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
Int J Urol; 2014 Apr; 21(4):377-81. PubMed ID: 24168232
[TBL] [Abstract][Full Text] [Related]
13. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
[TBL] [Abstract][Full Text] [Related]
14. Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.
Busch J; Magheli A; Leva N; Ferrari M; Kramer J; Klopf C; Kempkensteffen C; Miller K; Brooks JD; Gonzalgo ML
BJU Int; 2014 Oct; 114(4):517-21. PubMed ID: 24112652
[TBL] [Abstract][Full Text] [Related]
15. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients.
Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Anceschi U; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
Int Urol Nephrol; 2022 Oct; 54(10):2521-2528. PubMed ID: 35838831
[TBL] [Abstract][Full Text] [Related]
16. Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer.
Kovac E; Vertosick EA; Sjoberg DD; Vickers AJ; Stephenson AJ
BJU Int; 2018 Dec; 122(6):1003-1009. PubMed ID: 29802773
[TBL] [Abstract][Full Text] [Related]
17. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
18. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pathological and biochemical outcomes after radical prostatectomy in Korean patients with serum PSA ranges.
Lee HW; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
J Korean Med Sci; 2015 Mar; 30(3):317-22. PubMed ID: 25729256
[TBL] [Abstract][Full Text] [Related]
20. The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
Verep S; Erdem S; Ozluk Y; Kilicaslan I; Sanli O; Ozcan F
Prostate; 2019 Sep; 79(13):1523-1529. PubMed ID: 31269285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]